Market Overview

UPDATE: Barclays Begins Coverage on Cerner and Advisory Board

Related CERN
Fast Money Halftime Report Final Trade From December 16
Benzinga's Top Upgrades
Making Money With Charles Payne: 10/22/14 (Fox Business)
Related ABCO
Mid-Day Gainers From December 11: Lululemon, Office Depot, Calithera Biosciences, Heritage Financial
Mid-Morning Market Update: Markets Surge; Lululemon Profit Beats Expectations

Barclays Wednesday reports includes a note from analyst Eric Percher for coverage initiation on Cerner (NASDAQ: CERN) and The Advisory Board Company (NASDAQ: ABCO) with an Overweight rating for each company. Price target of $79.

Percher notes, "Given our findings that the transition to value-based reimbursement and implementation of population health tools on a large scale will be at least a five- to seven-year journey, we favor companies that either provide services which will enable the journey itself or have demonstrated opportunities to drive growth outside of population health offerings. We believe no company is better positioned to advise hospital leadership than Advisory Board and Cerner's diversified growth strategy should drive double-digit growth even absent meaningful population health contributions."

ABCO closed Tuesday at $66.79 and opened Wednesday morning at $67. CERN closed previous session at $61.86 and opened at $61.94.

Latest Ratings for CERN

Nov 2014Cowen & CompanyUpgradesMarket PerformOutperform
Oct 2014Credit SuisseMaintainsNeutral
Sep 2014Topeka CapitalMaintainsBuy

View More Analyst Ratings for CERN
View the Latest Analyst Ratings

Posted-In: BarclaysPrice Target Initiation Analyst Ratings


Related Articles (ABCO + CERN)

Around the Web, We're Loving...

Get Benzinga's Newsletters